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Abstract
Aims/hypothesis Treatment of diabetes secondary to total pancreatectomy remains a challenge and insulin constitutes the only
glucose-lowering treatment for these patients. We hypothesised that the glucagon-like peptide 1 (GLP-1) receptor agonist
lixisenatide would improve postprandial glucose tolerance in totally pancreatectomised patients.
Methods In a double-blinded, randomised, crossover study, 12 totally pancreatectomised individuals (age: 65.0 ± 9.5 mean±SD
years; BMI: 22.9 ± 3.9 kg/m2) and 12 healthy control individuals (age 66.1 ± 7.6 years; BMI: 24.0 ± 2.9 kg/m2) underwent two
3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of
lixisenatide or placebo. Basal insulin was given the night before each experimental day; no insulin was given during study days.
Results Compared with placebo, lixisenatide reduced postprandial plasma glucose excursions in the pancreatectomy group (baseline-
subtractedAUC [bsAUC] [mean±SEM]: 548 ± 125 vs 1447 ± 95mmol/l ×min, p < 0.001) and in the control group (−126 ± 12 vs 222
± 51 mmol/l ×min, p < 0.001). In the pancreatectomy group a mean peak glucose concentration of 23.3 ± 1.0 mmol/l was reached at
time point 134 ± 11 min with placebo, compared with a mean peak glucose concentration of 18 ± 1.4 mmol/l (p= 0.008) at time point
148 ± 13 min (p= 0.375) with lixisenatide. In the control group a mean peak concentration of 8.2 ± 0.4 mmol/l was reached at time
point 70 ± 13 min with placebo, compared with a mean peak concentration of 5.5 ± 0.1 mmol/l (p < 0.001) at time point 8 ± 25 min
(p= 0.054) with lixisenatide. Lixisenatide also reduced gastric emptying and postprandial glucagon responses in the pancreatectomy
group (66 ± 84 vs 1190 ± 311 pmol/l ×min, p= 0.008) and in the control group (141 ± 100 vs 190 ± 100 pmol/l ×min, p = 0.034). In
the pancreatectomy group, C-peptide was undetectable in plasma. In the control group, postprandial plasma C-peptide responses were
reduced with lixisenatide (18 ± 17 vs 189 ± 31 nmol/l ×min, p< 0.001).
Conclusions/interpretation The GLP-1 receptor agonist lixisenatide reduces postprandial plasma glucose excursions in totally
pancreatectomised patients. The mode of action seems to involve deceleration of gastric emptying and reduced postprandial
responses of gut-derived glucagon.
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(https://doi.org/10.1007/s00125-020-05158-9) contains peer-reviewed but
unedited supplementary material, which is available to authorised users.
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Introduction
The gut hormone glucagon-like peptide 1 (GLP-1) plays an
essential role in regulation of glucose homeostasis. In the
pancreas, GLP-1 potentiates glucose-induced insulin secretion
[1] and suppresses glucagon secretion [2], promoting glucose
disposal and inhibiting hepatic glucose production [3].
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Extrapancreatic effects of GLP-1 include decreased gastroin-
testinal motility [4], lowering of postprandial plasma triacyl-
glycerol concentrations [5], promotion of satiety [6, 7, 8] and
weight loss [8], lowering of systolic blood pressure and
cardiovascular and kidney protective effects during chronic
administration in patients with type 2 diabetes [9, 10]. Also,
an association between high basal concentrations of GLP-1
and increased resting energy expenditure (REE) has been
reported [11]. The complex and pleiotropic effects of GLP-1
combined with its potent effects on the pancreas make it diffi-
cult to disentangle pancreatic and extrapancreatic effects. For
example, regarding gastric emptying, appetite, food intake
and energy expenditure, it is difficult to discern whether the
mechanisms involve pancreatic effects (on insulin and gluca-
gon secretion) or exclusively rely on direct extrapancreatic
effects.
The present randomised, placebo-controlled, double-
blinded, crossover investigation of postprandial effects of the
short-acting GLP-1 receptor agonist lixisenatide in totally
pancreatectomised individuals and matched healthy control
participants was undertaken with two overall objectives: (1)
To disentangle extrapancreatic effects from pancreatic effects
of exogenous short-acting GLP-1 receptor agonist administra-
tion during a meal test by comparing the two groups, and (2)
to evaluate whether lixisenatide reduces postprandial glucose
excursions in patients with diabetes secondary to total pancre-
atectomy [12]; their diabetes is often referred to as erratic, with
frequent episodes of hypoglycaemia and hyperglycaemia,
making it difficult to control, especially postprandially. To
meet these objectives, we subjected totally pancreatectomised
individuals and matched healthy control participants to
standardised liquid mixed-meal tests following randomised,
double-blinded, single-dose injections of lixisenatide or
placebo.
Methods
Research design and methods The primary endpoint was the
effect of the short-acting GLP-1 receptor agonist lixisenatide
on postprandial plasma glucose excursions (as assessed by
baseline-subtracted AUC [bsAUC] from time −30 to
180 min) during a standardised liquid mixed-meal test)
compared with placebo in totally pancreatectomised patients.
Pre-specified secondary endpoints were C-peptide, glucose
and glycerol kinetics, gastric emptying assessed by paraceta-
mol absorption, glucagon, cholecystokinin (CCK), gastrin,
glucose-dependent insulinotropic polypeptide (GIP), GLP-1,
blood pressure, appetite, food intake, diuresis and REE. The
study was conducted at Gentofte Hospital, University of
Copenhagen, Hellerup, Denmark, in accordance with the
Helsinki Declaration (seventh revision, 2013), registered at
ClinicalTrials.gov (identifier NCT02640118) and approved
by the Ethics Committee of the Capital Region of Denmark
(registration no. H-15004078).
Study participants Twelve totally pancreatectomised individ-
uals (three women; age: [mean±SD] 65.0 ± 9.5 years; BMI:
22.9 ± 3.9 kg/m2) and 12 matched healthy control participants
(four women; age 66.1 ± 7.6 years; BMI: 24.0 ± 2.9 kg/m2)
with no family history of diabetes were included in this study
between August 2015 and July 2016 (Tables 1 and 2).
Matching criteria were age ± 20% and BMI ± 20%. All partic-
ipants gave informed consent to participate. A study flow
chart is presented in Electronic supplementary material
(ESM) Fig. 1.
Experimental procedures After a screening visit, participants
were examined on two study days within 2 months, separated
by at least 72 h. The participants were instructed to refrain
from strenuous physical exercise and any intake of alcohol
for 2 days prior to the screening visit and experimental days.
The pancreatectomised participants were instructed to take
their normal daily insulin doses the day before but not to take
any insulin in the morning of the experimental day. On both
experimental days, the participants met in our clinical research
facility after an overnight (10 h) fast and were placed in a
recumbent position in a hospital bed. Cannulas were inserted
in cubital veins, one for infusion of stable isotopes and one in a
contralateral vein for collection of arterialised blood (hand and
forearm wrapped in a heating pad [~50°C] throughout the
experimental day). The two experimental days were
performed in randomised order planned according to the
website www.random.org. The experiments were double-
blinded. An employee at the research unit, not involved in
the project, was responsible for handing out the correct
experimental medicine (lixisenatide pen or similar-looking
placebo pen) to the physician in charge of the experimental
days. After collection of basal blood samples, an infusion of
stable isotope-labelled glucose ([6,6-2H2]glucose; priming
dose of 17.6 μmol kg−1 × ϒ/5, where ϒ stands for fasting
plasma glucose in mmol/l, and continuous infusion of 0.
6 μmol kg−1 min−1) and glycerol ([1,1,2,3,3-2H5]glycerol;
priming dose of 2.0 μmol/kg and continuous infusion of
0.1 μmol kg−1 min−1) (Cambridge Isotope Laboratories,
Tewksbury, MA, USA) was initiated at time −120 min.
Isotope enrichment at different time points was calculated by
subtracting basal enrichment. The tracer/tracee ratio for glucose
is depicted in ESM Fig. 2. At time −30 min, either 20 μg of
lixisenatide or placebo was injected into the abdominal subcu-
tis. The presence of lixisenatide in plasma was verified using an
in-house RIA (data not shown). After 2 h of tracer infusions (to
obtain tracer steady state), at time 0 min, the participants
ingested a 200 ml liquid meal (containing 1650 kJ [394 kcal];
50% from carbohydrate, 15% from protein and 35% from fat)
consisting of glucose (47.2 g + 2.8 g [U-13C6]glucose), rapeseed
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Table 1 Clinical characteristics of the totally pancreatectomised individuals
Patient no. Sex (M/F) Time since
operation (years)
BMI (kg/m2) Insulin treatment (U) Reason for surgery Other treatment
1 M 6.0 29.4 Insulin detemir
24 + 14
Insulin aspart
7 + 7 + 7
Neuroendocrine tumour Creon 25,000 × 5; plus Creon 10,000
to snacks between meals
Paracetamol 665 mg × 6
Quinine 100 mg × 2
Lanzoprazole 30 mg × 1
Vitamin D 25 μg × 1
Glucosamine 400 mg × 3
Oxycodone hydrochloride 5 mg × 2
2 M 6.8 25.3 Insulin degludec
0 + 12
Insulin aspart
12 + 10 + 18
Adenocarcinoma Creon 25,000 × 2; Creon 35,000 × 1; plus
Creon 10,000 to snacks between meals
Pantoprazole 40 mg × 1
3 F 6.4 21.3 Insulin detemir
12 + 28
Insulin aspart
10 + 10 + 10
Adenocarcinoma Creon 25,000 × 3; plus Creon 10,000
to snacks between meals
Pantoprazole 40 mg × 1
Amlodipine 10 mg × 2
Bendroflumethiazide (2.5 mg) +
Potassium chloride (573 mg) × 2
4 M 6.3 25.7 Insulin glargine
8 + 12
Insulin aspart
10 + 0 + 10
Adenocarcinoma Creon 40,000 × 3; plus Creon 10,000 to
snacks between meals
Pantoprazole 40 mg × 2
5 F 2.3 17.1 Insulin detemir
9 + 6
Insulin aspart
4 + 2 + 4
IPMN Creon 25,000 × 3
6 M 2.3 20.9 Insulin detemir
12 + 0
Insulin aspart
5 + 5 + 5
Adenocarcinoma Creon 80,000 × 3; plus Creon
25,000 × 2 to snacks between meals
Pantoprazole 40 mg × 2
Mirtazapine 15 mg × 1
Citalopram 40 mg × 1
Magnesium 360 mg × 1
Loperamide 2 mg p.n.
7 M 0.3 22.0 Insulin detemir
14 + 6
Insulin aspart
2 + 2 + 2
Pancreatitis Creon 75,000 × 3
Tramadol 50 mg × 2
Pantoprazole 40 mg × 2
Melatonin 3 mg × 1
8 M 1.2 24.0 Insulin detemir
20 + 9
Insulin aspart
6 + 6 + 6
Adenocarcinoma Creon 50,000 × 3; plus Creon 50,000
to snacks between meals
Promethazine 25 mg × 1
Pantoprazole 40 mg × 2
Losartan potassium 100 mg × 1
Bendroflumethiazide 2.5 mg × 2
Amlodipine 5 mg × 1
9 M 4.0 19.5 Insulin detemir
17 + 7
Insulin aspart
7 + 4 + 4
Pancreatitis Creon 25,000 × 3
Pantoprazole 40 mg × 2
Buprenorphine 0.2 mg × 3
10 F 1.3 17.8 Insulin detemir
8 + 5
Insulin aspart
4 + 6 + 8
Adenocarcinoma Creon 25,000 × 4; plus Creon 25,000
to snacks between meals
Pantoprazole 20 mg × 1
Loperamide 4 mg × 1
11 M 1.0 23.2 Insulin detemir
16 + 12
Insulin aspart
8 + 8 + 8
Adenocarcinoma Creon 25,000 × 3; plus Creon 25,000
to snacks between meals
Centyl 2.5 mg × 1
Pantoprazole 40 mg × 2
12 M 0.4 28.5 Insulin detemir
15 + 15
Insulin aspart
6 + 6 + 6
IPMN Creon 25,000 × 3; plus Creon 25,000 to
snacks between meals
Bendroflumethiazide 2.5 mg × 1
Amlodipine 10 mg × 1
Ramipril 10 mg × 1
Spironolactone 25 mg × 1
Creon 10,000: 8000 amylase units, 10,000 lipase units and 600 protease units; Creon 25,000: 18,000 amylase units, 25,000 lipase units and 1000
protease units; Creon 40,000: 25,000 amylase units, 40,000 lipase units and 1600 protease units
IPMN, intraductal papillary mucinous neoplasm
1288 Diabetologia (2020) 63:1285–1298
oil [14.1 g], whey protein [15.2 g] and 1.5 g paracetamol) over
10 min. Pancreatectomised patients were given a standard
pancreatic enzyme supplement (Creon 25,000 lipase units,
Abbott, Orifarm, Odense, Denmark) with the meal. Pulse rate
and blood pressure were measured at time −120 min and every
30 min thereafter. Indirect calorimetry was performed over
15 min at time −90, 30 and 150 min for the measurement of
REE. At time 0, 30, 60, 90, 120, 150 and 180 min, hunger,
satiety, fullness and prospective food consumption were assessed
by visual analogue scales (VAS). At time 180 min, the partici-
pants were offered a standardised ad libitum meal consisting of
minced meat, pasta, corn, carrots, peppers, cream and salt and
pepper (50 energy [E]% carbohydrate, 37 E% fat, 13 E%
protein). Participants were instructed to eat until they felt
comfortably satisfied. The meal was consumed within a maxi-
mum of 30 min. Pancreatectomised patients were instructed to
take their regular pancreatic enzyme supplementation, half their
normal basal insulin dose and prandial insulin (according to plas-
ma glucose levels) together with the ad libitum meal. At the end
of the ad libitummeal, time spent eating,weight and total amount
of energy consumed were noted. The participants also evaluated
the taste, smell, visual appeal, aftertaste and overall palatability of
the meal using standardised VAS. Blood samples were drawn
120, 45, 30 and 15 min before and 10, 20, 30, 50, 70, 90, 120,
150, 180 min after ingestion of the liquid meal. The cannula was
flushed with 1 ml of saline (54 mmol/l NaCl) after every sample
was drawn. For bedside measurement of plasma glucose, blood
was collected in sodium fluoride tubes and centrifuged immedi-
ately at 7400 g for 2 min at room temperature. For the plasma
analysis of tracers, lixisenatide, GIP, GLP-1, glucagon, gastrin
and CCK, blood was collected in chilled tubes (on ice) contain-
ing EDTA and a specific dipeptidyl peptidase 4 inhibitor (valine
pyrrolidide, 0.01 mmol/l final concentration; a gift from Novo
Nordisk,Måløv, Denmark). For analysis of insulin andC-peptide
in serum, blood was sampled in plain tubes for coagulation
(20 min at room temperature). For plasma analysis of paraceta-
mol, blood was collected in chilled tubes (on ice) containing
lithium–heparin. All tubes were centrifuged for 20 min at
1200 g and 4°C. Plasma samples for GIP, GLP-1, glucagon,
CCK, gastrin and tracer analyses were stored at −20°C. Serum
samples for insulin and C-peptide analyses, plasma samples for
paracetamol and buffy coat from the first three EDTA tubes were
stored at −80°C until analysis.
Analyses Plasma glucose concentrations were measured at the
bedside using the glucose oxidase method (Yellow Springs
Instrument Model 2300 STAT Plus Analyzer, Yellow
Springs, OH, USA). Plasma glucagon concentrations were
assayed with a sandwich ELISA using N- and C-terminal
wrapping monoclonal antibodies (intra-assay CV 5.0%)
(Mercodia, Uppsala, Sweden) as previously described [13,
14]. Serum C-peptide concentrations were measured with a
two-site sandwich immunoassay using direct chemilumines-
cent technology (intra-assay CV 19%) (Siemens Healthcare,
Ballerup, Denmark) for the ADVIA Centaur XP. Plasma
enrichment of [6,6-2H2]glucose (intra-assay CV 3.2%),
[U - 1 3C 6 ] g l u c o s e ( i n t r a - a s s a y CV 3 . 5% ) a n d
[1,1,2,3,3-2H5]glycerol (intra-assay CV 3.1%) was deter-
mined using LC-MS/MS as previously described [15].
Amidated gastrin (intra-assay CV 5.0–11.4%), CCK, total
Table 2 Clinical characteristics
of the healthy control participants Control participant
no.
Sex
(M/F)
BMI (kg/m2) Treatment
1 M 29.4 Fluticasone 50 μg + salmeterol 500 μg × 1
Tiotropium bromide 18 mg × 1
2 M 18.3 –
3 F 20.7 Budesonide 160 μg + formoterol fumarate dihydrate
4.5 μg × 1
Losartan potassium 50 mg × 1
4 F 22.5 Zoledronate inj. 5 mg × 1 year
5 M 24.5 –
6 M 22.9 –
7 F 23.0 –
8 M 24.5 –
9 M 26.6 –
10 M 24.8 –
11 M 24.6 Simvastatin 40 mg × 1
Enalapril 20 mg × 1
12 F 26.8 –
F, female; M, male
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GIP, total GLP-1 and lixisenatide were measured with RIAs
(intra-assay CV 5.0%) as previously described [16–18]. REE
was measured by indirect calorimetry using a tight facemask
connected to the calorimeter, which measures the gas
exchange breath by breath via an O2 alkali cell and an infrared
CO2 sensor (CCMExpress, Medical Graphics Corporation, St
Paul, MN, USA). The calorimeter was calibrated immediately
before every measurement session. Metabolic rates are
presented as averages of measures carried out every 10th
second within a 12 min period. Gastric emptying was
measured according to the paracetamol absorption test [19,
20], appetite, hunger and satiety was evaluated using VAS
[21], and food intake was measured during the ad libitummeal
test as previously described [22].
Calculations and statistical analysis Our sample size calcula-
tions were based on a previous study looking at differences in
peak postprandial glucose values in patients with type 1 diabe-
tes and no residual beta cell function and infusions of either
saline or GLP-1 [18]. According to our calculations, eight
participants were needed to detect a difference in postprandial
glucose values of at least 6.0 mmol/l with a two-sided 5%
significance level and a power of 80%. As our experimental
protocol differs from the above, to avoid type 2 errors and to
ensure a power of >80%, we enrolled 12 pancreatectomised
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Fig. 1 Plasma glucose (a), C-
peptide (c), and paracetamol (e)
concentrations and corresponding
bsAUC results (b, d, f,
respectively) during a liquid
mixed-meal test (initiated at time
0 min) in 12 totally
pancreatectomised individuals
(PX) (red curves/circles/bar
outlines) and 12 healthy control
participants (CTRL) (blue curves/
triangles/bar outlines) with
preceding (−30 min) single-dose
administration of 20 μg
lixisenatide (filled symbols) or
placebo (open symbols).
***p < 0.001
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individuals and 12 matched healthy individuals. Data are
presented as mean±SEM unless otherwise stated. AUC values
were calculated using the trapezoid rule and are presented as
bsAUC unless otherwise stated. Glucose rate of appearance
(Ra) and glucose rate of disappearance (Rd) were calculated
from changes in glucose enrichment using the one-
compartment, fixed-volume, non-steady-state model of
Steele [23] and modified for use with stable isotopes and a
pool fraction of 70 ml/kg. Group differences in baseline char-
acteristics and AUCs were evaluated using two-sample
Student’s t test, paired tests within groups and unpaired tests
between groups. A p value of ≤0.05 was accepted as
Table 3 Glucose, hormones and paracetamol
Variable Totally pancreatectomised patients Healthy control participants
Lixisenatide Placebo p value Lixisenatide Placebo p value
Glucose
Mean baseline (mmol/l) 12.0 ± 0.5 11.3 ± 0.9 0.372 5.2 ± 0.1 5.1 ± 0.1 0.321
Cmax (mmol/l) 18 ± 1.4 23.3 ± 1 0.008 5.5 ± 0.1 8.2 ± 0.4 <0.001
Tmax (min) 148 ± 13 134 ± 11.1 0.375 8 ± 5.2 70 ± 13 0.054
AUC (mmol/l × min) 2715 ± 179 3475 ± 177 0.006 813 ± 13 1153 ± 57 <0.001
bsAUC (mmol/l ×min) 547 ± 125 1446 ± 95 <0.001 −125 ± 12 222 ± 51 <0.001
C-peptide
Mean baseline (nmol/l) 20.3 ± 3.9 17.8 ± 2.9 0.527 438 ± 38 401 ± 27.2 0.039
Cmax (nmol/l) 32.8 ± 15.2 29.5 ± 10.2 0.581 873 ± 134 2240 ± 282 <0.001
Tmax (min) −7.5 ± 15.3 0 ± 20.6 0.191 30 ± 8 99.2 ± 12.7 <0.001
AUC (nmol/l × min) 5.3 ± 2.2 4.2 ± 0.9 0.42 105 ± 19 261 ± 34 <0.001
bsAUC (nmol/l ×min) 1.6 ± 1.4 0.9 ± 0.8 0.34 17.8 ± 16.9 189 ± 31 <0.001
Paracetamol
Cmax (mmol/l) 0.1 ± 0.01 0.1 ± 0.01 <0.001 0.0 ± 0 0.1 ± 0 0.230
Tmax (min) 124 ± 14.6 95.8 ± 15.4 0.126 148 ± 14.6 135 ± 10.1 <0.001
AUC (mmol/l × min) 8.4 ± 1.3 16.5 ± 1.6 <0.001 3.9 ± 0.3 11.7 ± 1.2 <0.001
bsAUC (mmol/l ×min) 6.5 ± 1.3 13.5 ± 1.3 <0.001 2.4 ± 0.4 10 ± 1.1 <0.001
Glucagon
Mean baseline (pmol/l) 3.3 ± 0.8 2.8 ± 0.7 0.133 7.6 ± 1.2 6.5 ± 1.1 0.064
Cmax (pmol/l) 6.3 ± 1.4 14.1 ± 2.7 0.011 14.5 ± 3.34 10.7 ± 1.7 0.755
Tmax (min) 51.3 ± 21.9 73.3 ± 15.2 0.497 53.3 ± 21.2 25 ± 7.4 0.116
AUC (pmol/l × min) 620 ± 161 1479 ± 270 0.003 1283 ± 159 1253 ± 225 0.815
bsAUC (pmol/l ×min) 66.3 ± 84.2 1190 ± 311 0.008 141 ± 100 190 ± 99.5 0.034
CCK
Mean baseline (pmol/l) 1.0 ± 0.2 0.8 ± 0.1 0.194 0.9 ± 0.1 1.0 ± 0.1 0.718
Cmax (pmol/l) 3.9 ± 1.1 3.5 ± 0.7 0.599 2.7 ± 0.5 3.9 ± 0.6 0.071
Tmax (min) 45 ± 11.1 35.8 ± 6.1 0.366 75.8 ± 22.7 68 ± 16.2 0.776
AUC (pmol/l × min) 297 ± 83.4 297 ± 44.9 0.993 267 ± 53.5 362 ± 43.9 0.094
bsAUC (pmol/l ×min) 123 ± 75.8 150 ± 35.5 0.698 105 ± 46.7 140 ± 31.8 0.127
Gastrin
Mean baseline (pmol/l) 18.6 ± 5.6 19.2 ± 5.9 0.199 7.5 ± 0.4 78 ± 0.5 0.210
Cmax (pmol/l) 20.8 ± 6.3 25 ± 7.6 0.028 10 ± 0.6 12 ± 0.9 0.046
Tmax (min) −12.9 ± 5.6 44.6 ± 20.5 0.024 57.9 ± 18.9 77.1 ± 21.8 0.497
AUC (pmol/l × min) 2939 ± 882 3487 ± 1059 0.032 1522 ± 82 1788 ± 116 0.055
bsAUC (pmol/l ×min) −401 ± 162 26.5 ± 129 0.027 176 ± 73.3 393 ± 102 0.089
GLP-1
Mean baseline (pmol/l) 17.9 ± 2.0 18.1 ± 1.7 0.914 11.6 ± 1.2 11.2 ± 1.3 0.821
Cmax (pmol/l) 50.4 ± 10.2 143.4 ± 41.2 0.038 18.8 ± 3.1 27.8 ± 3.9 0.046
Tmax (min) 66.7 ± 21.4 42.5 ± 12.3 0.343 15.8 ± 8.9 53.3 ± 13.8 0.045
AUC (pmol/l × min) 4240 ± 582 8865 ± 1599 0.011 1609 ± 168 3020 ± 283 <0.001
bsAUC (pmol/l ×min) 1025 ± 592 5615 ± 1412 0.016 −481 ± 186 1005 ± 297 0.006
GIP
Mean baseline (pmol/l) 15.9 ± 3.1 16.6 ± 2.8 0.553 10.2 ± 1.0 9.0 ± 1.8 0.609
Cmax (pmol/l) 67.9 ± 13.7 112.2 ± 19.9 0.430 18.9 ± 2.5 77.1 ± 9.4 <0.001
Tmax (min) 105 ± 17.6 71.7 ± 15 0.248 13.3 ± 13.9 93.3 ± 16.4 0.008
AUC (pmol/l × min) 6143 ± 1319 12,714 ± 2243 0.003 1508 ± 410 9735 ± 1392 <0.001
bsAUC (pmol/l ×min) 3278 ± 941 9729 ± 1828 0.003 −322 ± 445 8115 ± 1357 <0.001
Plasma/serum baseline concentration, maximal concentration (Cmax) and time to peak concentration (Tmax) of glucose, C-peptide, glucagon, GLP-1, GIP,
CCK, gastrin and paracetamol during a liquid mixed-meal test with 1.5 g paracetamol after single-dose injection of 20 μg of lixisenatide or placebo in
totally pancreatectomised individuals (n = 12) and healthy control participants (n = 12). Data are mean ± SEM. Statistical analysis was performed by
paired two-sample Student’s t test (two-tailed) within groups
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statistically significant. GraphPad Prism, version 7 (La Jolla,
CA, USA) was used for statistical evaluation and generating
graphs of results.
Results
Plasma glucose Basal concentrations of glucose were higher
in the pancreatectomy group compared with the control group
(Fig. 1a). During the OGTT, a peak mean concentration of
23.3 ± 1.0 mmol/l was reached at time point 134 ± 11 min in
the pancreatectomy group with placebo compared with a peak
mean glucose concentration of 18 ± 1.4 mmol/l (p = 0.008) at
time point 148 ± 13 min (p = 0.375) with lixisenatide. In the
control group, a peak mean concentration of 8.2 ± 0.4 mmol/l
was reached at time point 70 ± 13 min on the placebo day
compared with a peak mean concentration of 5.5 ±
0.1 mmol/l (p < 0.001) at time point 8 ± 25 min (p = 0.054)
with lixisenatide. Postprandial glucose excursions (bsAUCs)
were reduced with lixisenatide compared with placebo in both
the totally pancreatectomised participants (548 ± 125 vs 1447
± 95 mmol/l × min, p < 0.001) and in the healthy control
participants (−126 ± 12 vs 222 ± 51 mmol/l × min, p < 0.001)
(Fig. 1b and Table 3).
C-peptide Serum C-peptide concentrations in the totally
pancreatectomised participants were below the detection limit
of the assay (<16 pmol/l) on both experimental days at all time
points. However, two patients (one who was operated because
of a neuroendocrine tumour [patient 1] and another because of
an adenocarcinoma [patient 8]) showed very low levels of C-
peptide (lower than what is needed to define C-peptide nega-
tivity [24]) with peak values of 35 pmol/l at time 90 min
(patient 1) and 199 pmol/l at time 120 min (patient 8) after
lixisenatide administration. Other endpoints, including gluca-
gon, were not different in these patients compared with the
mean group values, and thus data from these patients were
kept in the dataset for the following analyses. In the healthy
control participants, postprandial C-peptide responses were
reduced with lixisenatide compared with placebo (17.8 ±
16.9 vs 189 ± 31 nmol/l × min, p < 0.001) (Fig. 1c,d and
Table 3).
Glucose and glycerol kinetics Baseline levels of total glucose
Ra and total glucose Rd were higher in the pancreatectomy
group compared with the control group (p < 0.001 for both
measures) (Fig. 2a,c). In both groups, total glucose Ra was
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Fig. 3 Plasma glucagon
concentrations (a, b) and plasma
glucagon responses (c, d) during
liquid mixed−meal test (initiated
at time 0 min) in 12 totally
pancreatectomised participants
(PX) (red curves/circles/bar
outlines) and 12 healthy control
participants (CTRL) (blue curves/
triangles/bar outlines) with
preceding (−30 min) single-dose
administration of 20 μg
lixisenatide (filled symbols) or
placebo (open symbols). AUCs
(c) and baseline-subtracted AUCs
(bsAUC) (d) are also shown.
*p < 0.05, **p < 0.01
Fig. 2 Glucose kinetics. Total glucose rate of appearance (Ra) (a), total
glucose rate of disappearance (Rd) (c), endogenous glucose production
(EGP) Ra (e) and oral glucose Ra (g) during the liquid mixed-meal test
(initiated at time 0 min) in 12 totally pancreatectomised individuals (PX)
(red curves/circles/bar outlines) and 12 healthy control participants
(CTRL) (blue curves/triangles/bar outlines) with preceding (−30 min)
single-dose administration of 20 μg lixisenatide (closed symbols) or
placebo (open symbols). The corresponding bsAUC results (b, d, f, h)
are also shown. **p < 0.01, ***p < 0.001
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higher with placebo compared with lixisenatide (pancreatec-
tomy group, bsAUC 61.3 ± 20 vs −36.5 ± 11mmol, p = 0.003;
control group, bsAUC 49.2 ± 12 vs −37.6 ± 12 mmol,
p < 0.001) (Fig. 2b). Total glucose Rd was also higher with
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Fig. 4 Plasma CCK (a), gastrin
(c), GLP-1 (e) and GIP (g)
concentrations and corresponding
baseline-subtracted AUC
(bsAUC) results (b, d, f, h,
respectively) during a liquid
mixed-meal test (initiated at time
0 min) in 12 totally
pancreatectomised individuals
(PX) (red curves/circles/bar
outlines) and 12 healthy control
participants (CTRL) (blue curves/
triangles/bar outlines) with
preceding (−30 min) single-dose
administration of 20 μg
lixisenatide (filled symbols) or
placebo (open symbols).
*p < 0.05, **p < 0.01,
***p < 0.001
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placebo in both groups (pancreatectomy group, bsAUC 11.1
± 19 vs −53.4 ± 9.4 mmol, p = 0.008; control group, bsAUC
46.5 ± 13 vs −33.8 ± 12mmol, p < 0.001) (Fig. 2d). There was
no significant difference in postprandial endogenous glucose
production between lixisenatide and placebo (pancreatectomy
group, bsAUC −91.1 ± 7.2 vs −84.3 ± 6.8 mmol, p = 0.371;
healthy control group, bsAUC −79.9 ± 4.3 vs −82.2 ±
4.8 mmol, p = 0.659) (Fig. 2f). Ra of oral glucose was lower
with lixisenatide in both groups (pancreatectomy group,
bsAUC 51.0 ± 10 vs 141 ± 18 mmol, p = 0.003; healthy
control group, bsAUC 42.0 ± 11 vs 131 ± 13 mmol,
p < 0.001) (Fig. 2h).
Baseline concentrations of plasma glycerol were
higher in the totally pancreatectomised participants than
in the healthy control participants (p < 0.001). In the
pancreatectomy group there was no significant differ-
ence in plasma glycerol levels between the two study
days (bsAUC, p = 0.284). In the control group, plasma
concentrations of glycerol were lower with placebo
compared with lixisenatide (bsAUC −7284 ± 943 vs
−3858 ± 1746 μmol/l × min, p = 0.05). There was no
significant difference in levels of glycerol Ra (bsAUC,
p = 0.677) or Rd (bsAUC, p = 0.652) between the two
study days in the pancreatectomy group. Both glycerol
Ra (bsAUC −21.7 ± 2.3 vs −5.4 ± 3.1 mmol, p < 0.001)
and Rd (bsAUC −21.5 ± 2.3 vs −5.3 ± 2.9 mmol,
p < 0.001) were lower with placebo compared with
lixisenatide in the healthy control group (ESM Fig. 3).
Paracetamol Postprandial concentrations of serum paraceta-
mol were reduced with lixisenatide compared with placebo in
both the totally pancreatectomised participants (6.5 ± 1.3 vs
13.5 ± 1.3 mmol/l × min, p < 0.001) and the control group
(2.4 ± 0.4 vs 10 ± 1.1 mmol/l × min, p < 0.001), illustrating a
reduced rate of gastric emptying (nutrient entry into the small
intestine) in both groups on the day with lixisenatide admin-
istration (Fig. 1e,f and Table 3).
Glucagon Basal plasma concentrations of glucagon in the
pancreatectomy group were above the detection limit
(1 pmol/l) of the applied ELISA but were lower than
those in the control group (2.9 ± 0.5 vs 6.79 ± 0.8 pmol/l,
p = 0 .005 ) (F i g . 3 ) . Wi t h p l a c ebo , t h e t o t a l l y
pancreatectomised patients exhibited larger glucagon
responses (1190 ± 311 vs 190 ± 99.5 pmol/l × min,
p = 0.006) and numerically higher peak concentrations (14.1 ±
2.7 vs 10.7 ± 1.7 pmol/l, p= 0.298) compared with the healthy
control participants. Lixisenatide reduced postprandial glucagon
responses (bsAUC) compared with placebo in the pancreatecto-
my group (66.3 ± 84.2 vs 1190 ± 311 pmol/l ×min, p= 0.008)
and the control group (141 ± 100 vs 190 ± 99.5 pmol/l ×min,
p = 0.034) (Fig. 3 and Table 3).
CCK and gastrin Baseline concentrations of CCK were similar
between the pancreatectomy group and the control group
(0.89 ± 0.1 vs 0.93 ± 0.1 pmol/l, p = 0.84) (Fig. 4a,b and
Table 3). In both groups, a rise in postprandial CCK concen-
trations was observed, but there was no significant difference
between study days in either of the two groups. Baseline
concentrations of gastrin were higher in the pancreatectomy
group (18.9 ± 3.9 vs 7.6 ± 0.3 pmol/l × min, p = 0.063) (Fig.
4c,d and Table 3). Lixisenatide lowered postprandial gastrin
concentrations compared with placebo in both the pancreatec-
tomy group (−401 ± 162 vs 26.5 ± 129 pmol/l × min, p = 0.027)
and the control group (176 ± 75.3 vs 393 ± 102 pmol/l ×min,
p = 0.089), yet only significantly in the pancreatectomy group.
Lixisenatide, GLP-1 and GIP Injection of 20 μg of lixisenatide
resulted in a plasma concentration of approximately 70 pmol/l
measured 2 h after injection. Baseline concentrations of GLP-
1 were higher in the pancreatectomy group compared with the
control group (17.9 ± 1.3 vs 11.4 ± 0.8 pmol/l, p = 0.002).
With placebo, the pancreatectomy group showed an eightfold
higher peak value in GLP-1 concentration at the 20 min time
point compared with the control group (122 ± 45 vs 14 ±
2.2 pmol/l, p = 0.028). In both the pancreatectomy group
(1025 ± 592 vs 5615 ± 1412 pmol/l × min, p = 0.016) and the
control group (−481 ± 186 vs 1005 ± 297 pmol/l × min, p =
0.006), postprandial GLP-1 responses (bsAUC) were reduced
by lixisenatide compared with placebo (Fig. 4e,f and Table 3).
Baseline concentrations of GIP were higher in the pancreatec-
tomy group (16.3 ± 2.0 vs 9.6 ± 1.0 pmol/l, p = 0.038).
Lixisenatide reduced postprandial GIP responses (bsAUC)
compared with placebo in both the pancreatectomy group
(3278 ± 941 vs 9729 ± 1828 pmol/l × min, p = 0.003) and the
control group (−322 ± 445 vs 8115 ± 1357 pmol/l × min,
p < 0.001) (Fig. 4g,h and Table 3).
Data on appetite scores, food intake (ESM Table 1, ESM
Fig. 4), blood pressure, pulse (ESM Fig. 5) and REE are
presented in the ESM Results.
Discussion
We assessed postprandial effects of single-dose treatment with
the GLP-1 receptor agonist lixisenatide (vs placebo) in totally
pancreatectomised patients and show (1) a clear reduction in
postprandial plasma glucose excursions, (2) attenuation of
robust postprandial plasma glucagon responses and (3) a
deceleration of gastric emptying.
Total pancreatectomy entails dramatic anatomical changes,
including resection of the distal 2–3 cm of the antrum and
removal of the pyloric sphincter and the duodenum [12].
Using a mass spectrometry-validated [14] and highly specific
glucagon sandwich ELISA targeting the N- and C-terminal
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regions of glucagon simultaneously, we observed significantly
lower basal plasma concentrations of glucagon in totally
pancreatectomised participants, but—as we have previously
described with an OGTT [25]—we saw robust postprandial
plasma glucagon responses in these individuals. Interestingly,
the rise in postprandial plasma glucagon concentrations in the
totally pancreatectomised patients was eliminated by admin-
istration of a single dose of the GLP-1 receptor agonist
lixisenatide. What is the explanation for postprandial gluca-
gon secretion in totally pancreatectomised patients and how
does lixisenatide eliminate this increase? Our previous find-
ings showing grossly elevated glucagon responses to oral
glucose and suppression of plasma glucagon concentrations
after intravenous glucose in totally pancreatectomised patients
support a gut-derived origin of glucagon in these individuals
[25]. We believe that proglucagon-producing enteroendocrine
cells in the gut (so-called L cells) may constitute a potential
origin of glucagon secretion. L cells are found throughout the
intestinal tract and are highly abundant in the jejunum [26].
Because of the altered gastrointestinal anatomy following
Whipple’s procedure with total pancreatectomy (not pylorus-
preserving), nutrients are delivered directly from the stomach
to the jejunum after ingestion. This unretarded and direct
delivery of nutrients to L cell-rich segments of the small intes-
tine causes massive stimulation of L cells, reflected by the
eightfold greater postprandial peak plasma GLP-1 concentra-
tions in our totally pancreatectomised patients. Also, other
proglucagon-derived L cell products, such as oxyntomodulin,
have been shown to circulate at much higher concentrations in
these individuals [25]. It is generally believed that prohormone
convertase 1/3 processes proglucagon to GLP-1, glucagon-like
peptide 2 and glicentin, which is further processed to
oxyntomodulin, in enteroendocrine L cells, and that prohormone
convertase 2, processing proglucagon to glucagon, is restricted to
the pancreatic alpha cells [27]. Currently, the mechanisms under-
lying gut-derived glucagon secretion remain obscure, but they
may involve the presence of prohormone convertase 2 in
proglucagon-producing enteroendocrine cells [25, 27] and/or
unspecific processing by prohormone convertase 1/3. In totally
pancreatectomised individuals, the latter may feasibly result in
detectable concentrations of prohormone convertase 1/3 products
owing to themassive postprandial stimulation of L cell-rich areas
of the small intestines. The elimination of the postprandial gluca-
gon response in our totally pancreatectomised participants by
administration of lixisenatide may be driven by the deceleration
of gastric emptying, reducing the flow of nutrients to the intesti-
nal L cells. On that note, the lixisenatide-induced deceleration of
gastric emptying (as previously observed in individuals with
intact pancreas) in our totally pancreatectomised participants
clearly must be categorised as an extrapancreatic effect of
lixisenatide. Nevertheless, we cannot exclude a direct suppres-
sive effect of lixisenatide on extrapancreatic glucagon secretion
in our totally pancreatectomised volunteers.
When investigating glucose kinetics, we found that Ra of
oral glucose and total glucose Ra and Rd were higher with
placebo in both study groups. These findings underline the
slowing effect lixisenatide has on gastric emptying and nutri-
ent delivery to the gut. The higher baseline Ra and Rd of glyc-
erol observed in the totally pancreatectomised participants
indicate a higher rate of lipolysis in this group. These glycerol
findings are in line with those of Lund et al [25] and are most
likely explained by the insulin-deficient state of the pancrea-
tectomy group since insulin inhibits lipolysis.
We show significantly higher baseline concentrations of
gastrin in the totally pancreatectomised group compared with
the control group, mainly driven by higher concentrations in
two of the totally pancreatectomised patients. Lund et al found
lower concentrations of gastrin in totally pancreatectomised indi-
viduals comparedwith healthy control individuals [25] and, simi-
larly, Rehfeld et al found gastrin concentrations to be low or
below the detection limit in patients who had undergone
Whipple’s surgery [28]. Notably, however, pancreatectomy using
Whipple’s operation at the time of the experiments by Rehfeld
et al. would have involved total or almost total antrectomy [28].
Moreover, totally pancreatectomised patients today are usually
treated with proton pump inhibitors, which stimulates antral G
cell secretion of gastrin.
Diabetes secondary to total pancreatectomy is classified as
a disease of the exocrine pancreas by the American Diabetes
Association [29] and World Health Organization [30] (previ-
ously it has been classified as type 3c diabetes). This form of
diabetes is often characterised by erratic fluctuations in plasma
glucose concentrat ions and frequent episodes of
hypoglycaemia and hyperglycaemia, with the latter constitut-
ing a profound problem postprandially for these patients. No
specific treatment guidelines exist, but the primary target is to
maintain HbA1c < 53 mmol/l (<7%) to minimise the risk of
microvascular complications [31, 32]. Currently, there are no
randomised controlled trial data available to help develop
guidelines on glucose-lowering treatments specific to this type
of diabetes, and the standard insulin therapy used in these
patients is based on empirical knowledge. Insulin replacement
therapy in totally pancreatectomised individuals is a necessity,
but it is associated with hypoglycaemia, limiting compliance
and treatment success. In recent years, GLP-1 receptor
agonists have been implemented in the treatment of patients
with type 2 diabetes, but a demarcation of the pancreatic and
extrapancreatic effects of these agents has been difficult to
establish. The present study is, to our knowledge, the first to
provide controlled evidence of an incretin-based—in fact,
any—glucose-lowering drug for the treatment of
hyperglycaemia in diabetes secondary to total pancreatecto-
my. Lixisenatide is a short-acting GLP-1 receptor agonist and
therefore less prone to tachyphylaxis when it comes to gastric
emptying [33], thus providing sustained reductions of post-
prandial glucose concentrations during long-term use [34, 35].
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In the present study, single-dose lixisenatide significantly
reduced postprandial plasma glucose excursions in individ-
uals with diabetes secondary to total pancreatectomy. The
mechanisms behind this observation may involve
lixisenatide-induced deceleration of gastric emptying and/or
attenuation of postprandial glucagon responses. The present
results are unlikely to have an immediate impact on clinical
practice; larger and longer-term clinical trials are warranted.
An important strength of this study is the double-blinded,
placebo-controlled, crossover design, which reduces the influ-
ence of inter-individual confounding factors. However, some
limitations need to be mentioned. First, we did not achieve
complete steady state according to our tracer/tracee ratio at
baseline (ESM Fig. 2), which may contribute to the decrease
in the Ra of glucose in the fasting state observed in both the
pancreatectomy group and the control group. However, this
was evident on both experimental days and did not differ
between study days in either of the groups and is therefore
unlikely to explain the differences in glucose kinetics between
the interventions. Second, totally pancreatectomised individ-
uals are deficient in pancreatic enzymes and depend on
supplements of amylase, protease and lipase in order to absorb
nutrients sufficiently [36]. Therefore, in our study the
pancreatectomised individuals ingested a single dose of
Creon (enzyme supplement) just before the liquid meal on
both study days. Nevertheless, we expect absorption to be
different in the two study groups, which should be taken into
account when comparing the two groups. Furthermore, we did
not collect urine during the experiments. We expect that more
glucose was excreted through urine during the meal test with
placebo (highest plasma glucose concentrations) than with
lixisenatide treatment in the totally pancreatectomised
participants.
In conclusion, the short-acting GLP-1 receptor agonist
lixisenatide reduced postprandial plasma glucose excursions
in a cohort of totally pancreatectomised individuals. Themode
of action may involve lixisenatide-induced deceleration of
gastric emptying and/or elimination of postprandial responses
of gut-derived glucagon in these patients.
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